Trials / Completed
CompletedNCT00649194
Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg
Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Delayed-Release Tablets (20 mg; Mylan) to Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Mylan Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets relative to Eisai's Aciphex® delayed-release 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fed conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rabeprazole Sodium Delayed-Release Tablets 20 mg | 20mg, single dose fed |
| DRUG | Aciphex® Tablets 20 mg | 20mg, single dose fed |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2003-08-01
- Completion
- 2003-08-01
- First posted
- 2008-04-01
- Last updated
- 2024-04-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00649194. Inclusion in this directory is not an endorsement.